Azilsartan medoxomil NDC 70748-237

NDC codes

FDA NDC Directory

Product NDC (as listed)70748-237Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70748-0237Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70748-237-06	70748023706	30 TABLET in 1 BOTTLE (70748-237-06)Marketed from May 14, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Azilsartan medoxomil
Generic name (nonproprietary): azilsartan medoxomil
Active ingredients: Azilsartan kamedoxomil — 80 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Lupin Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214489
Marketing start: May 14, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Angiotensin 2 Type 1 Receptor Antagonists (Mechanism)Decreased Blood Pressure (Physiologic effect)
Identifiers: Product ID 70748-237_f05aba4d-376f-460f-9264-ecf267e04dcdSPL ID f05aba4d-376f-460f-9264-ecf267e04dcdSPL set ID b1c8de43-3b26-408f-8c7e-6c7d76348199RxCUI 1091646, 1091652UPC 0370748237069, 0370748236062
Pharmacologic class: Angiotensin 2 Receptor Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470748023706 followed by a unit qualifier and the quantity

Package 70748-0237-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 13, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Azilsartan medoxomil tablets are indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with azilsartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic ther…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 214489

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214489
Product	Strength	Form · route	Labeler	Product NDC
Azilsartan medoxomil	Azilsartan kamedoxomil 40 mg/1	TabletOral	Lupin Pharmaceuticals, Inc.	70748-236